Group 1 - Advanced Biomed Inc. has entered into an agreement to sell 100% of its Hong Kong subsidiary for a total purchase price of US$23,000 based on a valuation report [1] - The transaction includes the transfer of all intellectual property owned by the Hong Kong subsidiary, including that of its wholly owned subsidiary, Shanghai Sglcell Biotech Co., Ltd. [2] - The CEO of Advanced Biomed stated that the divestment is part of a strategic realignment to centralize clinical trials in Taiwan due to evolving regulatory requirements in China [3] Group 2 - The company operates through its Taiwan subsidiary, which has developed a proprietary microfluidic platform for advanced circulating tumor cell detection and analysis [4] - The product portfolio includes devices and biochips designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in Taiwan and plans for global expansion [4]